title: Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice.
abstract: Heart failure is accompanied by severely impaired beta-adrenergic receptor (betaAR) function, which includes loss of betaAR density and functional uncoupling of remaining receptors. An important mechanism for the rapid desensitization of betaAR function is agonist-stimulated receptor phosphorylation by the betaAR kinase (betaARK1), an enzyme known to be elevated in failing human heart tissue. To investigate whether alterations in betaAR function contribute to the development of myocardial failure, transgenic mice with cardiac-restricted overexpression of either a peptide inhibitor of betaARK1 or the beta2AR were mated into a genetic model of murine heart failure (MLP-/-). In vivo cardiac function was assessed by echocardiography and cardiac catheterization. Both MLP-/- and MLP-/-/beta2AR mice had enlarged left ventricular (LV) chambers with significantly reduced fractional shortening and mean velocity of circumferential fiber shortening. In contrast, MLP-/-/betaARKct mice had normal LV chamber size and function. Basal LV contractility in the MLP-/-/betaARKct mice, as measured by LV dP/dtmax, was increased significantly compared with the MLP-/- mice but less than controls. Importantly, heightened betaAR desensitization in the MLP-/- mice, measured in vivo (responsiveness to isoproterenol) and in vitro (isoproterenol-stimulated membrane adenylyl cyclase activity), was completely reversed with overexpression of the betaARK1 inhibitor. We report here the striking finding that overexpression of this inhibitor prevents the development of cardiomyopathy in this murine model of heart failure. These findings implicate abnormal betaAR-G protein coupling in the pathogenesis of the failing heart and point the way toward development of agents to inhibit betaARK1 as a novel mode of therapy.
authors.affiliation: Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. hrockman@med.unc.edu
authors.forename: H A
authors.initials: HA
authors.lastname: Rockman
authors.forename: K R
authors.initials: KR
authors.lastname: Chien
authors.forename: D J
authors.initials: DJ
authors.lastname: Choi
authors.forename: G
authors.initials: G
authors.lastname: Iaccarino
authors.forename: J J
authors.initials: JJ
authors.lastname: Hunter
authors.forename: J
authors.initials: J
authors.lastname: Ross
authors.forename: R J
authors.initials: RJ
authors.lastname: Lefkowitz
authors.forename: W J
authors.initials: WJ
authors.lastname: Koch
mesh_terms: D000818:Animals; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology*; D004791:Enzyme Inhibitors; D054769:G-Protein-Coupled Receptor Kinase 2; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D006333:Heart Failure / Q000235:genetics* / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D051552:beta-Adrenergic Receptor Kinases
chemical_list: D004791:Enzyme Inhibitors; D017868:Cyclic AMP-Dependent Protein Kinases; C496567:GRK2 protein, human; D051552:beta-Adrenergic Receptor Kinases; D054769:G-Protein-Coupled Receptor Kinase 2